The emerging role of anti-angiogenic therapy in ovarian cancer (review)

Vincenza Conteduca, Barbara Kopf, Salvatore Luca Burgio, Emanuela Bianchi, Dino Amadori, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

The introduction of new therapeutic agents into clinical practice of ovarian cancer, in addition to the role of surgery and chemotherapy, has been the subject of numerous studies because this tumor remains worldwide the most lethal gynecological cancer. It is now known that angiogenesis plays a vital role for ovarian physiology, but also in ovarian carcinogenesis and so it has become the main target of ovarian cancer treatment. In this review, the most common molecular pathways of angiogenesis have been investigated leading to the identification of novel targets, including monoclonal antibodies and tyrosine kinase inhibitors. The fundamental targets of anti-angiogenic drugs are vascular endothelial growth factor receptor and its ligand, but also platelet-derived growth factor, fibroblast growth factor and angiopoietin. Moreover, improved knowledge of angiogenic process allowed the discovery of other molecules, such as semaphorins, neuropilins, clusterin, some transcriptional factors, and the identification of features, including stemness, epithelial-mesenchymal transition, downregulation of certain microRNAs, the alteration of immune system, that contribute to angiogenesis and possibly to resistance mechanisms. The following patent and literature review aim to highlight recent findings of approved and novel anti-angiogenic drugs that make the treatment of patients with ovarian cancer a rapidly growing field of oncology.

Original languageEnglish
Pages (from-to)1417-1424
Number of pages8
JournalInternational Journal of Oncology
Volume44
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Ovarian Neoplasms
Angiogenesis Inhibitors
Neuropilins
Angiopoietins
Semaphorins
Clusterin
Vascular Endothelial Growth Factor Receptor
Epithelial-Mesenchymal Transition
Fibroblast Growth Factors
Platelet-Derived Growth Factor
MicroRNAs
Protein-Tyrosine Kinases
Immune System
Neoplasms
Carcinogenesis
Therapeutics
Down-Regulation
Monoclonal Antibodies
Ligands
Drug Therapy

Keywords

  • Angiogenesis
  • Bevacizumab
  • Chemotherapy
  • Epithelial ovarian cancer
  • Monoclonal antibody
  • Tyrosine kinase inhibitor
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The emerging role of anti-angiogenic therapy in ovarian cancer (review). / Conteduca, Vincenza; Kopf, Barbara; Burgio, Salvatore Luca; Bianchi, Emanuela; Amadori, Dino; De Giorgi, Ugo.

In: International Journal of Oncology, Vol. 44, No. 5, 2014, p. 1417-1424.

Research output: Contribution to journalArticle

Conteduca, Vincenza ; Kopf, Barbara ; Burgio, Salvatore Luca ; Bianchi, Emanuela ; Amadori, Dino ; De Giorgi, Ugo. / The emerging role of anti-angiogenic therapy in ovarian cancer (review). In: International Journal of Oncology. 2014 ; Vol. 44, No. 5. pp. 1417-1424.
@article{4d7499016c9c4d6bb693c9eca9bdff34,
title = "The emerging role of anti-angiogenic therapy in ovarian cancer (review)",
abstract = "The introduction of new therapeutic agents into clinical practice of ovarian cancer, in addition to the role of surgery and chemotherapy, has been the subject of numerous studies because this tumor remains worldwide the most lethal gynecological cancer. It is now known that angiogenesis plays a vital role for ovarian physiology, but also in ovarian carcinogenesis and so it has become the main target of ovarian cancer treatment. In this review, the most common molecular pathways of angiogenesis have been investigated leading to the identification of novel targets, including monoclonal antibodies and tyrosine kinase inhibitors. The fundamental targets of anti-angiogenic drugs are vascular endothelial growth factor receptor and its ligand, but also platelet-derived growth factor, fibroblast growth factor and angiopoietin. Moreover, improved knowledge of angiogenic process allowed the discovery of other molecules, such as semaphorins, neuropilins, clusterin, some transcriptional factors, and the identification of features, including stemness, epithelial-mesenchymal transition, downregulation of certain microRNAs, the alteration of immune system, that contribute to angiogenesis and possibly to resistance mechanisms. The following patent and literature review aim to highlight recent findings of approved and novel anti-angiogenic drugs that make the treatment of patients with ovarian cancer a rapidly growing field of oncology.",
keywords = "Angiogenesis, Bevacizumab, Chemotherapy, Epithelial ovarian cancer, Monoclonal antibody, Tyrosine kinase inhibitor, Vascular endothelial growth factor",
author = "Vincenza Conteduca and Barbara Kopf and Burgio, {Salvatore Luca} and Emanuela Bianchi and Dino Amadori and {De Giorgi}, Ugo",
year = "2014",
doi = "10.3892/ijo.2014.2334",
language = "English",
volume = "44",
pages = "1417--1424",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - The emerging role of anti-angiogenic therapy in ovarian cancer (review)

AU - Conteduca, Vincenza

AU - Kopf, Barbara

AU - Burgio, Salvatore Luca

AU - Bianchi, Emanuela

AU - Amadori, Dino

AU - De Giorgi, Ugo

PY - 2014

Y1 - 2014

N2 - The introduction of new therapeutic agents into clinical practice of ovarian cancer, in addition to the role of surgery and chemotherapy, has been the subject of numerous studies because this tumor remains worldwide the most lethal gynecological cancer. It is now known that angiogenesis plays a vital role for ovarian physiology, but also in ovarian carcinogenesis and so it has become the main target of ovarian cancer treatment. In this review, the most common molecular pathways of angiogenesis have been investigated leading to the identification of novel targets, including monoclonal antibodies and tyrosine kinase inhibitors. The fundamental targets of anti-angiogenic drugs are vascular endothelial growth factor receptor and its ligand, but also platelet-derived growth factor, fibroblast growth factor and angiopoietin. Moreover, improved knowledge of angiogenic process allowed the discovery of other molecules, such as semaphorins, neuropilins, clusterin, some transcriptional factors, and the identification of features, including stemness, epithelial-mesenchymal transition, downregulation of certain microRNAs, the alteration of immune system, that contribute to angiogenesis and possibly to resistance mechanisms. The following patent and literature review aim to highlight recent findings of approved and novel anti-angiogenic drugs that make the treatment of patients with ovarian cancer a rapidly growing field of oncology.

AB - The introduction of new therapeutic agents into clinical practice of ovarian cancer, in addition to the role of surgery and chemotherapy, has been the subject of numerous studies because this tumor remains worldwide the most lethal gynecological cancer. It is now known that angiogenesis plays a vital role for ovarian physiology, but also in ovarian carcinogenesis and so it has become the main target of ovarian cancer treatment. In this review, the most common molecular pathways of angiogenesis have been investigated leading to the identification of novel targets, including monoclonal antibodies and tyrosine kinase inhibitors. The fundamental targets of anti-angiogenic drugs are vascular endothelial growth factor receptor and its ligand, but also platelet-derived growth factor, fibroblast growth factor and angiopoietin. Moreover, improved knowledge of angiogenic process allowed the discovery of other molecules, such as semaphorins, neuropilins, clusterin, some transcriptional factors, and the identification of features, including stemness, epithelial-mesenchymal transition, downregulation of certain microRNAs, the alteration of immune system, that contribute to angiogenesis and possibly to resistance mechanisms. The following patent and literature review aim to highlight recent findings of approved and novel anti-angiogenic drugs that make the treatment of patients with ovarian cancer a rapidly growing field of oncology.

KW - Angiogenesis

KW - Bevacizumab

KW - Chemotherapy

KW - Epithelial ovarian cancer

KW - Monoclonal antibody

KW - Tyrosine kinase inhibitor

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84899096671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899096671&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2334

DO - 10.3892/ijo.2014.2334

M3 - Article

C2 - 24626312

AN - SCOPUS:84899096671

VL - 44

SP - 1417

EP - 1424

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -